Biopharmaceutical CMO Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The biopharmaceutical cmo market size has grown rapidly in recent years. It will grow from $21.72 billion in 2023 to $24.68 billion in 2024 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, globalization, rise in healthcare expenditure, regulatory support, increased research funding.
The biopharmaceutical cmo market size is expected to see rapid growth in the next few years. It will grow to $41.87 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to rise in telehealth and remote trials, global health initiatives, rise in disposable income, global health initiatives. Major trends in the forecast period include advanced therapies dominance, digitalization and industry 4.0, continuous manufacturing, sustainability and green practices.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/biopharmaceutical-cmo-global-market-report
Scope Of Biopharmaceutical CMO Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Biopharmaceutical CMO Market Overview
Market Drivers –
An increase in the robustness of venture capital investments for the life science sector is expected to propel the growth of the biopharmaceutical CMO market. The life sciences sector refers to the businesses and organizations that conduct research and development on living beings. The robustness of venture capital investments is a feature describing the capacity of a model, test, or system to function correctly when its parameters or presumptions are changed. As the investment in the life science sector increases, there will be an increase in the manufacturing of biopharmaceuticals. For instance, in September 2021, according to JLL, a US-based company specializing in investment consultancy, the record amount of venture capital was raised in the UK over the last three months, with £1.9 billion raised between 1 June and 26 August 2021. This incredible investment brings the UK total for 2021 to £4.25 billion ($5.787 billion) YTD, up from £2.8 billion in 2020. Therefore, an increase in the robustness of venture capital investments for the life science sector is driving the biopharmaceutical CMO market growth.
The biopharmaceutical cmo market covered in this report is segmented –
1) By Product: Biologics, Biosimilars
2) By Source: Mammalian, Non-Mammalian
3) By Service: Manufacturing, Fill And Finish Operations, Analytical And QC Studies, Packaging
Get an inside scoop of the biopharmaceutical cmo market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=7771&type=smp
Regional Insights –
North America was the largest region in the biopharmaceutical CMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biopharmaceutical cmo market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major companies operating in the biopharmaceutical cmo market include Lonza Group AG, Fujifilm Diosynth Biotechnologies USA Inc., Thermo Fisher Scientific Inc., Samsung BioLogics Co. Ltd., WuXi Biologics Co. Ltd., Lonza Ltd., JRS Pharma Group, CMC Biologics AS, Catalent Inc., Boehringer Ingelheim GmbH, Rentschler Biopharma SE, AGC Biologics Inc., Abzena Ltd., AbbVie Inc., AstraZeneca plc, Bayer AG, Biogen Inc., Bristol-Myers Squibb Co., Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding Ag, Sanofi SA, Takeda Pharmaceuticals Co., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Company, Moderna BioTechnology Company
Table of Contents
1. Executive Summary
2. Biopharmaceutical CMO Market Report Structure
3. Biopharmaceutical CMO Market Trends And Strategies
4. Biopharmaceutical CMO Market – Macro Economic Scenario
5. Biopharmaceutical CMO Market Size And Growth
…..
27. Biopharmaceutical CMO Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
